Citizens JMP lowered the firm’s price target on Crinetics (CRNX) to $86 from $90 and keeps an Outperform rating on the shares post the Q2 update. The company is preparing for its first approval in acromegaly with four Phase 3 trials set to start in the near term, the analyst tells investors in a research note. The firm thinks Palsonify is likely to be approved for acromegaly by its September 25 FDA action date.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics Pharmaceuticals Reports Q2 2025 Financial Results
- Crinetics Pharmaceuticals: Promising Outlook with Anticipated Approval of Palsonify and Strategic Market Launch
- Crinetics reports Q2 EPS ($1.23), consensus ($1.10)
- 3 Best Stocks to Buy Now, 7/22/2025, According to Top Analysts
- Crinetics Pharmaceuticals’ Palsonify Gains Positive Endorsement for Acromegaly Treatment with Promising Pipeline Expansion